Annemarie Kleefstra brings 18+ years of managing Phase I–IV trials and submissions in rare diseases, oncology, and clinical development strategy. She’s been instrumental to biotech companies in evaluating clinical strategy, identifying opportunities, and mitigating potential risks.
Annemarie Kleefstra
